文献速递痛风与晶体性关节病

口服降尿酸药物治疗侵蚀性痛风的强化血清尿酸降低:一项随机双盲对照试验

Intensive Serum Urate Lowering With Oral Urate-Lowering Therapy for Erosive Gout: A Randomized Double-Blind Controlled Trial.
PubMed 文献 · Arthritis Rheumatol · 2022-04-11

这项为期2年的随机双盲对照试验纳入104例基线血清尿酸≥0.30毫摩尔/升、正在口服降尿酸治疗的侵蚀性痛风患者,比较强化目标<0.20毫摩尔/升与标准目标<0.30毫摩尔/升。结果显示强化组血清尿酸水平显著更低,但第2年达标率更低(62% vs 83%),且两组CT骨侵蚀评分均小幅增加、组间无差异(P=0.20)。结论认为口服降尿酸治疗下强化降尿酸难以实现,带来高用药负担,且不改善骨侵蚀评分。

要点

  • 强化组血清尿酸水平显著低于标准组(P=0.002),但第2年达标率更低(62% vs 83%,P<0.05)。
  • 强化组别嘌醇剂量更高(平均±标准差746±210毫克/天 vs 497±186毫克/天,P<0.001),联合治疗更多(P=0.0004)。
  • 两组CT骨侵蚀评分2年均小幅增加,组间无差异(P=0.20);OMERACT核心结局均改善且组间无差异。

核心结论

  • 与血清尿酸目标<0.30毫摩尔/升相比,口服降尿酸治疗下强化降尿酸难以实现,带来高用药负担,且不改善侵蚀性痛风患者的骨侵蚀评分。

研究设计与样本

  • 为期2年的随机双盲对照试验,纳入104例接受口服降尿酸治疗且基线血清尿酸≥0.30毫摩尔/升的侵蚀性痛风患者。
  • 参与者随机分配至强化目标<0.20毫摩尔/升组或标准目标<0.30毫摩尔/升组(后者按风湿病学指南视为标准)。
  • 口服降尿酸治疗采用标准化方案滴定至目标,使用别嘌醇、丙磺舒、非布司他和苯溴马隆的最大批准剂量。
  • 主要终点为CT总骨侵蚀评分,OMERACT痛风核心结局域为次要终点。

主要发现

  • 研究期间强化目标组血清尿酸水平显著低于标准目标组(P=0.002)。
  • 第2年强化目标组达标率更低:强化组62% vs 标准组83%(P<0.05)。
  • 强化目标组别嘌醇剂量更高:平均±标准差746±210毫克/天 vs 497±186毫克/天(P<0.001)。
  • 强化目标组接受更多联合治疗(P=0.0004)。
  • 两组CT骨侵蚀评分2年均小幅增加,组间无差异(P=0.20);OMERACT核心结局域(痛风发作、痛风石、疼痛、患者总体疾病活动度评估、健康相关生活质量、活动受限)两组均改善且组间无差异;不良事件和严重不良事件发生率组间相似。

关键数值与推荐

  • 强化血清尿酸目标为<0.20毫摩尔/升,标准目标为<0.30毫摩尔/升(按风湿病学指南视为标准)。
  • 基线纳入条件为血清尿酸≥0.30毫摩尔/升。
  • 主要终点CT总骨侵蚀评分组间比较P=0.20。
  • 第2年达标率强化组62% vs 标准组83%(P<0.05)。
  • 别嘌醇平均剂量强化组746±210毫克/天 vs 标准组497±186毫克/天(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether a therapeutic approach of intensive serum urate lowering results in improved bone erosion scores in patients with erosive gout. METHODS: We undertook a 2-year, double-blind randomized controlled trial of 104 participants with erosive gout who were receiving serum urate-lowering therapy orally and who had serum urate levels of ≥0.30 mmoles/liter at baseline. Participants were randomly assigned to either an intensive serum urate target of <0.20 mmoles/liter or a standard target of <0.30 mmoles/liter (considered the standard according to rheumatology guidelines). Oral serum urate-lowering therapy was titrated to target using a standardized protocol (with the maximum approved doses of allopurinol, probenecid, febuxostat, and benzbromarone). The primary end point was the total computed tomography (CT) bone erosion score. Outcome Measures in Rheumatology (OMERACT) gout core outcome domains were secondary end points. RESULTS: Although the serum urate levels were significantly lower in the intensive target group compared to the standard target group over the study period (P = 0.002), fewer participants in the intensive target group achieved the randomized serum urate target level by year 2 (62% versus 83% of patients in the standard target group; P < 0.05). The intensive target group required higher doses of allopurinol (mean ± SD 746 ± 210 mg/day versus 497 ± 186 mg/day; P < 0.001) and received more combination therapy (P = 0.0004) compared to the standard target group. We observed small increases in CT bone erosion scores in both serum urate target groups over 2 years, with no between-group difference (P = 0.20). OMERACT core outcome domains (gout flares, tophi, pain, patient's global assessment of disease activity, health-related quality of life, and activity limitation) improved in both groups over 2 years, with no between-group differences. Adverse event and serious adverse event rates were similar between the groups. CONCLUSION: Compared to a serum urate target of <0.30 mmoles/liter, more intensive serum urate lowering is difficult to achieve with an oral urate-lowering therapy. Intensive serum urate lowering leads to a high medication burden and does not improve bone erosion scores in patients with erosive gout.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Dalbeth N, Doyle AJ, Billington K, et al. Intensive Serum Urate Lowering With Oral Urate-Lowering Therapy for Erosive Gout: A Randomized Double-Blind Controlled Trial. Arthritis Rheumatol. 2022. PMID: 34927391. doi:10.1002/art.42055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。